Remove Disease Remove Molecular Biology Remove Protein Expression Remove Treatment
article thumbnail

The mechanism of Semen Persicae?Flos Carthami in treating hypertrophic scar: A study based on network pharmacological analysis and in vitro experiments

Chemical Biology and Drug Design

However, the pharmacodynamic mechanism and molecular target of SP-FC in the treatment of HS are still unclear. Therefore, this study is intended to explore the mechanism and target of SP-FC in the treatment of HS through network pharmacology combined with in vitro cell and molecular biology experiments.

article thumbnail

Women in Stem with Dr Beate Mueller-Tiemann

Drug Target Review

I always found science fascinating, but I really fell in love with it in high school when I was introduced to biochemistry and molecular biology. Biochemistry and molecular biology fascinated me in school. I did my PhD project on elucidating the role of the p53 protein that is relevant in many cancers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Enhancing gene therapy with Circio

Drug Target Review

Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in protein expression and durability have been demonstrated by the circVec 2.1

article thumbnail

The future outlook for mRNA therapies

Drug Discovery World

Whilst research into mRNA has been ongoing for decade, interest has sparked in recent years and research has begun to expand into areas of vaccinology, infectious diseases and other indications. mRNA-based approaches can produce proteins / peptides by using protein synthesis which is processed in a transfected cell 1.

Therapies 130
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Advances in discovery and engineering of antibodies for non-cancer targets This session will feature a range of presentations which include: Joshua Tan, PhD, Chief, Antibody Biology Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, on: ‘Discovery of broadley-neutralising antibodies against Coronaviruses’.

article thumbnail

BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen

The Pharma Data

Food and Drug Administration gave it the green light to initiate a Phase III study of tesamorelin for the treatment of adults with Nonalcoholic Steatohepatitis (NASH) with liver fibrosis. based Mogrify Limited expanded its research collaboration with MRC Laboratory of Molecular Biology. This week, the company said the U.S.